Aditxt Inc. (NASDAQ: ADTX) has announced that Saundra Pelletier, CEO of Evofem Biosciences—its pending acquisition target—has been honored with the Trailblazing Female Founders Award at the 2025 STIMULATE Conference in Nashville. This recognition underscores Pelletier's leadership in advancing women's sexual and reproductive health through Evofem's innovative products, including the hormone-free contraceptive PHEXXI(R) and SOLOSEC(R), an oral treatment for bacterial vaginosis and trichomoniasis.
The award coincides with Say Vagina Month, a campaign initiated by Evofem to foster open and accurate discussions about vaginal health. This initiative highlights the company's commitment to breaking taboos and promoting health education. Aditxt's anticipated acquisition of Evofem, expected to be finalized in the second half of 2025, signifies a strategic expansion into women's health, complementing its existing programs focused on immune and precision health.
Aditxt's innovative platform aims to democratize health innovations by fostering collaboration among research institutions, industry partners, and shareholders. The acquisition of Evofem is subject to several conditions, including shareholder approval and Aditxt's ability to raise approximately $17 million to fulfill its financial obligations. The successful completion of this transaction could mark a significant milestone in Aditxt's mission to address societal health challenges through collective progress.
For more information on Aditxt's initiatives and updates, visit https://ibn.fm/ADTX.
